InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Werewolf Therapeutics, Inc.

HOWL Clue Score19
United States Fiscal year ends December CIK 0001785530
$0.98 +0.22% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.98 −93.85% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 30 Apr 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2020Operating income−22.4Net income−15.0EPS, diluted−28.08Fiscal year 2021Operating income−50.1Net income−50.0EPS, diluted−10.94Fiscal year 2022Operating income−56.1Net income−53.8EPS, diluted−1.86Fiscal year 2023Operating income−40.5Net income−37.4EPS, diluted−1.05Fiscal year 2024Operating income−73.6Net income−70.5EPS, diluted−1.63Fiscal year 2025Operating income−60.7Net income−60.8EPS, diluted−1.33
FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −22.4 −50.1 −56.1 −40.5 −73.6 −60.7
Net income −15.0 −50.0 −53.8 −37.4 −70.5 −60.8
Growth
EPS, diluted −28.08 −10.94 −1.86 −1.05 −1.63 −1.33

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−18.6Capital expenditure−0.6Free cash flow−19.2Fiscal year 2021Operating cash flow−42.9Capital expenditure−0.5Free cash flow−43.4Fiscal year 2022Operating cash flow−40.6Capital expenditure−3.6Free cash flow−44.2Fiscal year 2023Operating cash flow−32.6Capital expenditure−0.8Free cash flow−33.4Fiscal year 2024Operating cash flow−56.2Capital expenditure−0.3Free cash flow−56.4Fiscal year 2025Operating cash flow−60.3Capital expenditure0.0Free cash flow−60.3
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −18.6 −42.9 −40.6 −32.6 −56.2 −60.3
Capital expenditure −0.6 −0.5 −3.6 −0.8 −0.3 0.0
Free cash flow −19.2 −43.4 −44.2 −33.4 −56.4 −60.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2020Cash92.6Shareholders’ equity−51.9Fiscal year 2021Cash157.5Shareholders’ equity152.8Fiscal year 2022Cash129.3Shareholders’ equity122.3Fiscal year 2023Cash134.3Total debt40.0Net cash (debt)94.3Shareholders’ equity111.4Debt to equity0.36Fiscal year 2024Cash111.0Total debt32.1Net cash (debt)78.9Shareholders’ equity73.4Debt to equity0.44Fiscal year 2025Cash57.1Total debt32.1Net cash (debt)25.0Shareholders’ equity24.8Debt to equity1.29
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 92.6 157.5 129.3 134.3 111.0 57.1
Total debt n/a n/a n/a 40.0 32.1 32.1
Net cash (debt) n/a n/a n/a 94.3 78.9 25.0
Shareholders’ equity −51.9 152.8 122.3 111.4 73.4 24.8
Debt to equity n/a n/a n/a 0.36 0.44 1.29

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022† 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
16.6 35.3 53.8 41.8 56.4 44.8
5.8 14.8 18.7 18.7 19.0 15.8
−22.4 −50.1 −56.1 −40.5 −73.6 −60.7
Growth
n/a n/a n/a n/a n/a 0.0
−15.0 −50.0 −53.8 −37.4 −70.5 −60.8
Growth
Per share
−28.08 −10.94 −1.86 −1.05 −1.63 −1.32
−28.08 −10.94 −1.86 −1.05 −1.63 −1.33
Growth
1.0 18.5 28.9 35.6 43.3 46.0
1.0 18.5 28.9 35.6 43.9 46.8
Growth +1,736.3% +56.4% +23.5% +23.0% +6.7%

† The diluted share count jumps at 2021 and 2022, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 6 of 6 years on file.